A peptide, deliberately shaped
Making a medicine of PT-141
PT-141’s closed peptide ring earns my admiration as a made object. The questions begin when that design meets delivery, desire and unwanted effects.
The chemical starting point
In a survey of peptide and oligonucleotide drugs approved during 2019, bremelanotide appears among medicines examined for their structures, targets and adverse effects. For me, that survey puts “medicinal” within reach of a molecular model: someone has deliberately shaped a compound, and the shape has consequences.
PT-141 is easy to describe through its sexual effects alone. I am equally curious about its chemical shape. Its closed ring, the route used to deliver it and the amount of unwanted activity it produces all help explain the medicine that eventually reached approval. The ingenuity deserves attention. So does the friction.
What is PT-141?
PT-141 is the research name for bremelanotide, a synthetic melanocortin receptor agonist. A peptide is a short chain of amino acids; this one joins seven into a ring. The cyclic structure gives it greater stability than related linear peptides. That is a useful piece of chemical design, before any claim about desire enters the picture.
Its central action involves melanocortin receptors in the brain, especially MC4R and MC3R. Early work found erectile activity in men as well as erections and brain-cell activation in rats and nonhuman primates. The animal observations and the human observations remain distinct findings in that early pharmacology report.
Delivery
A stable peptide still has to reach the body in a workable preparation. PT-141 was explored as a nasal spray before development settled on an injection beneath the skin; early intranasal development ended because drug exposure was too variable. The prescribing information describes the approved subcutaneous preparation.
The delivery problem can interrupt a tidy chemical success story. A compound can produce an interesting response while its delivery still needs work. The delivery and dosage notes follow that problem through the routes studied and the blood-level measurements.
The human result
The two Phase 3 trials in 1,267 premenopausal women with HSDD found modest improvements in sexual desire and distress over low desire during 24 weeks. HSDD means persistently low desire that causes marked distress. The 52-week extension found sustained improvements, with nausea remaining the main tolerability problem.
Those experiences bring the ingenious chemical design down to earth. A medicine for distressing low desire has a practical burden if feeling sick makes it hard to continue. The results and side effects deserve time together.
The approved use
FDA approval on June 21, 2019 covered bremelanotide injection for acquired, generalized HSDD in premenopausal women. The label excludes men, postmenopausal women and sexual-performance enhancement from the approved use. Material described as a PT-141 research chemical sits outside that pharmaceutical approval.
The remaining notes examine the peptide’s design and mechanism, the specified use and the published sources. “Medicinal” is an absorbing word precisely because the chemistry has to meet all these practical conditions.